Cantel Medical Subsidiary Mar Cor Purification Given 510(k) Clearance For MINNCARE® HD Disinfectant For Use In Water System Disinfection In Kidney Dialysis Applications

... First disinfectant cleared by FDA for water system disinfection in hemodialysis

Jan 15, 2015, 16:16 ET from Cantel Medical Corp.

LITTLE FALLS, N.J., Jan. 15, 2015 /PRNewswire/ -- Mar Cor Purification, Inc. (Mar Cor), a subsidiary of Cantel Medical Corp. (NYSE: CMN)  announced today that it has been given 510(k) clearance (K133724) from the FDA for MINNCARE® HD high level disinfectant, the first water system disinfectant granted a medical device clearance for use in hemodialysis applications.  MINNCARE HD disinfectant is a proprietary blend of peracetic acid and hydrogen peroxide and is completely biodegradable allowing for easy disposal and reducing environmental impact.  The non-medical device version, MINNCARE® Cold Sterilant, is considered the gold standard in water system disinfection and is used daily in a variety of markets and applications.

MINNCARE HD disinfectant was developed to address the critical need for a validated water system disinfectant that is both safe and effective.  After developing an effective protocol with the FDA, Mar Cor successfully conducted extensive testing to validate product performance and safety.  Together with MINNCARE HD disinfectant, Mar Cor will offer validated test strips for testing strength and to verify that there are no residuals following a disinfection procedure. Both products will be available in early February 2015.

John Rickert, VP Medical Sales, noted, "MINNCARE HD disinfectant eliminates the risk of using unregulated industrial chemicals, such as chlorine bleach, in patient treatment areas.  The disinfection protocol is validated, the chemistry has been proven efficacious, and accurate test strips are available to insure dosage, as well as to verify complete rinse-out of the disinfectant.  The use of MINNCARE HD disinfectant in a dialysis clinic will help maintain the water system in optimum condition and make it easier for the water system operator to complete an effective disinfection."

MINNCARE® is a registered trademark of Medivators Inc. (a Cantel Medical Company)

About Cantel Medical Corp.
Cantel Medical Corp. (NYSE: CMN) Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives.  Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products.  For more information, go to our website www.cantelmedical.com.

About Mar Cor Purification, Inc.
Mar Cor Purification, Inc., a wholly-owned subsidiary of Cantel Medical Corp. (NYSE: CMN), is a water purification company and is the largest supplier of dialysis medical water systems in North America. It has service facilities in 3 cities in the United States and Canada including seven ion exchange resin regeneration plants strategically located in Atlanta, Boston, Chicago, Philadelphia, San Antonio, Montreal and Toronto. Mar Cor also provides turnkey water purification systems to high purity clients including pharmaceutical, cosmetics, semiconductor and other bacteria controlled applications. Unique hollow fiber filtration/separation products and Peracetic acid (PAA) disinfectants are provided through a worldwide distributor network. Visit our website at www.mcpur.com to find out more about Mar Cor Purification. http://www.mcpur.com/main/filtertech.html

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

SOURCE Cantel Medical Corp.



RELATED LINKS

http://www.cantelmedical.com